Fintech PR

Artprice by Art Market: Top 10 Auction Gains in H1 2019

Published

5 years ago

September 2, 2019

Newsfile

Reading Time: 4 minutes

The resale of artworks illustrates the financial potential of Art, a potential that depends on numerous factors including the artists’ notoriety, the intrinsic qualities of the works and, of course, the intensity of demand over time. While the average return on art investments is approximately 4.6% p.a. for an average duration of 13 years, certain works obviously generate much better returns, especially in the Contemporary Art segment.

For thierry Ehrmann, Founder/CEO of Artprice: “the most profitable artists on the Art Market are no longer the great Moderns, as in the last century. Major buyers have transferred their investments onto the most recognised Contemporary artists – onto the great “classics” of our era – artists like Jean-Michel Basquiat and Yayoi Kusama who now represent a sort of holy grail for any museum or any major collector and who are enjoying ever-growing and ever more international demand. The Contemporary Art Market offers opportunities for capital gains that were unimaginable 20 years ago.”

Contemporary Art Generates the Best Returns

Contemporary creation is today more profitable than Post-War art. There is only one Western Post-War artist among the top 10 gains hammered during the first six months of 2019: Alexander Calder, with a rare mobile sculpture (Fish), the price of which has risen from less than $200,000 to more than $17.5 million since the end of the 1980s. Contemporary artists are clearly dominant in the rankings. They account for seven of the ten best gains hammered during the period and concern works by Jean-Michel Basquiat, Daniel Buren, Yayoi Kusama, Pierre Soulages and Christopher Wool. Contemporary Art (the overall price index of which rose 40% in H1 2019) is the most profitable segment of the Art Market. The prices of certain works have been multiplied in range from 30 to more than 300 times versus their previous auction values.

Long holding

The volatility of the Contemporary Art market makes it particularly favourable for certain types of investment. It allows quick gains (with holding times of three to ten years) on some highly popular signatures such as Kaws, George Condoand Sean Scully. Of course, rapid turnarounds on art are not risk-free, particularly on the younger signatures and it is probably wiser to gamble on artists whose work and whose secondary market are both mature.

Moreover, the most profitable resales require a lot of patience with the best gains coming from long-term holding periods. The most spectacular price increases concerned works sold publicly in the 1980s and 1990s and which are now returning to auction. Eight of the ten best gains in our ranking concern works that began to be sold publicly more than 20 years ago.

The biggest price increase concerns a work by Jean-Michel Basquiat, Apex, which had not been auctioned for 31 years (it changed owner three times during that time, but privately). Apex is a major work, first appearing at auction in June 1988, two months before the artist’s death. Regarded as one of his best paintings, it fetched $29,400 in 1988, joining the artist’s top 10 results. The posthumous growth of his prices had not started yet. It was only three years after Basquiat’s death that one of his works crossed the $100,000 threshold for the first time, blithely tripling its high estimate (Red rabbit, 1982, on 11 November 1988 at Sotheby’s). When it was offered to the public last March, Apex fetched $10.8 million, posting an exceptional gain of +36,685% in 31 years.

Remember that Jean-Michel Basquiat is the first and only Contemporary artist whose work has crossed the $100 millionthreshold on the auction market (Untitled, 1982, on 18 May 2017 at Sotheby’s New York). This pillar of the Contemporary Art Market – whose overall price index has risen +1,608% since 2000 – accounts for three of the top ten most profitable resales since the beginning of the year.

Jean-Michel Basquiat

©thierry Ehrmann – courtesy of Organ Museum / Abode of Chaos

Top 10 auction gains in H1 2019

1. Jean-Michel Basquiat: Apex (1986) +36,685% in 31 years
$10,815,000 on 5 March 2019 – Sotheby’s London
$29,400 on 30 June 1988 – Christie’s London

2. Daniel Buren: Peinture acrylique blanche (1968) +10,111% in 22 years
$357,400 on 8 March 2019 – Phillips London
$3,500 on 26 February 1997 – Libert-Castor Paris

3. Alexander Calder: Fish (1952) +8,752% in 32 years
$17,527,000 on 15 May 2019 – Christie’s New York
$198,000 on 4 November 1987 – Sotheby’s New York

4. Fengmian Lin: Wisteria +7,182% in 27 years
$1,321,700 on 2 April 2019 – Sotheby’s Hong Kong
$18,150 on 1 June 1992 – Sotheby’s New York

5. Yayoi Kusama: Midsummer (1983) +5,840% in 19 years
$427,700 on 6 March 2019 – Sotheby’s London
$7,200 on 30 June 2000 – Sotheby’s London

6. Fei’an Yu: Parrot (1945) +5,600% in 29 years
$786,600 on 2 April 2019 – Sotheby’s Hong Kong
$13,800 on 15 November 1990 – Sotheby’s Hong Kong

7. Jean-Michel Basquiat: Untitled (1987) +4,617% in 26 years
$1,321,000 on 5 March 2019 – Sotheby’s London
$28,000 on 25 March 1993 – Christie’s London

8. Pierre Soulages: Painting 130 x 89 cm, 2 March 1961+3,402% in 32 years
$3,046,900 on 5 June 2019 – Sotheby’s Paris
$87,000 on 2 July 1987 – Sotheby’s London

9. Christopher Wool: Untitled (1986) +3,324% in 21 years
$630,000 on 27 June 2019 – Phillips London
$18,400 on 13 November 1998 – Christie’s New York

10. Jean-Michel Basquiat: Soothsayer (1983) +2,924% in 17 years
$998,000 on 5 March 2019 – Sotheby’s London
$33,000 on 28 June 2002 – Christie’s London

Two living French artists among the most profitable

Two French artists still active today, Pierre Soulages and Daniel Buren, stand out thanks to the opening of the International Market. They are among the very rare Contemporary French artists who have managed to build a reputation and a price structure outside France, especially in New York from where both have hammered their personal records ($10.6 million obtained for Soulages in November 2018 at Christie’s and $2.1 million for Buren last May at the same auctioneer). Soulages’ abstract style and Buren’s minimalist style correspond to two trends that are both currently highly sought-after on the American art market.

The value added to Daniel Buren’s Peinture acrylique blanche sur tissu rayé blanc rouge (1968) is particularly noteworthy. The price of this work has multiplied 102 times in 22 years – the time it took for demand to consolidate abroad. Until recently, most of Buren’s high-quality works sold badly in the Big Apple… when they were not bought in.

In addition, Peinture acrylique blanche sur tissu rayé blanc rouge was auctioned at the right time, while Daniel Burenwas installing a monumental work on the High Line in New York. The artist has signed the Big Apple by floating thousands of flags over New Yorkers, flags bearing the 8.7-cm-wide colored stripes that are so characteristic of his work (exhibition En Plein Air visible until March 2020). An ideal piece of artistic ‘news’ to convince New Yorkers to buy the French veteran of Minimalism.

As with the stock markets, investments in art require a permanent follow-up from collectors of the news concerning the artists in the portfolios. The construction, maintenance and inflation of an artist’s prices depends primarily, as with equity markets, on information. It is information which allows us to select the most opportune moment for a resale and the best-suited marketplace to ensure the best possible added value.

SOURCE Artprice.com

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

2 weeks ago

April 5, 2024

CISION (PR Newswire)

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf	Invitation to presentation of EQT AB’s Q1 Announcement 2024
https://news.cision.com/eqt/i/eqt-ab-group,c3285895	EQT AB Group

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

2 weeks ago

April 5, 2024

CISION (PR Newswire)

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs

Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

2 weeks ago

April 5, 2024

CISION (PR Newswire)

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html